Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | TK2 | O00142 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514375 | 0.88 | CD69 (0.36) | CD69TK2 | |
| SCHEMBL8911352 | 0.88 | ALDH1A1 (0.44) | — | |
| SCHEMBL5144529 | 0.84 | CDA (0.41) | ADORA3 | |
| SCHEMBL9092454 | 0.84 | TYMP (0.41) | CD69 | |
| SCHEMBL9711038 | 0.79 | TK2 (0.44) | CD69TK2 | |
| SCHEMBL9135382 | 0.79 | LGALS9 (0.38) | TK2 | |
| SCHEMBL31685600 | 0.75 | TK2 (0.44) | MEN1KMT2ATK2 | |
| SCHEMBL4460471 | 0.75 | ALDH1A1 (0.34) | — | |
| SCHEMBL3414315 | 0.75 | ALDH1A1 (0.45) | — | |
| SCHEMBL1271665 | 0.74 | TK1 (0.46) | TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1108724-B1 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | SIRNA THERAPEUTICS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-5962675-A | Chemical syntheses of 2'-O-methoxy purine nucleosides | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | UMPS, PNP, NUDT1 | MEN1 588/4885KMT2A 1224/4885CD69 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.